secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001493152-23-032195
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem amends SPA: $97.5M notes repurchasable for up to $25M; default withdrawn
-------------------------------------------------------------------------------

- Investor withdraws March 2023 Notice of Default; waives all existing Events of Default.
- Notes no longer convertible into common stock, removing dilution from over 240M reserved shares.
- Evofem can repurchase Notes over 5 years for $14M–$25M, down from $97.5M outstanding balance.
- $1M upfront payment due Oct 1, 2023; quarterly cash payments up to 5% of global net product revenues.
- Notes continue to accrue 10% interest; failure to repurchase by Sept 8, 2028 allows full collection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223032195/0001493152-23-032195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223032195/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer